End-of-day quote
Taipei Exchange
06:00:00 2024-07-11 pm EDT
|
5-day change
|
1st Jan Change
|
22.05
TWD
|
-3.08%
|
|
-11.62%
|
-43.82%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,237
|
3,874
|
6,459
|
17,123
|
8,548
|
5,582
|
Enterprise Value (EV)
1 |
3,115
|
3,948
|
6,285
|
16,685
|
8,309
|
5,643
|
P/E ratio
|
-9.27
x
|
-13.5
x
|
-15.7
x
|
-38.7
x
|
-31.4
x
|
-15.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
35.5
x
|
46.5
x
|
72.7
x
|
209
x
|
39.2
x
|
88
x
|
EV / Revenue
|
34.1
x
|
47.4
x
|
70.8
x
|
204
x
|
38.1
x
|
89
x
|
EV / EBITDA
|
-10.8
x
|
-17.6
x
|
-20.4
x
|
-43.2
x
|
-32.2
x
|
-17
x
|
EV / FCF
|
-15.6
x
|
-49.4
x
|
-36.7
x
|
-126
x
|
-84.1
x
|
-36.8
x
|
FCF Yield
|
-6.42%
|
-2.03%
|
-2.72%
|
-0.8%
|
-1.19%
|
-2.71%
|
Price to Book
|
3.6
x
|
5.68
x
|
7.34
x
|
17.8
x
|
11.2
x
|
13.9
x
|
Nbr of stocks (in thousands)
|
114,032
|
115,757
|
132,227
|
132,227
|
142,227
|
142,227
|
Reference price
2 |
28.39
|
33.47
|
48.85
|
129.5
|
60.10
|
39.25
|
Announcement Date
|
4/11/19
|
4/1/20
|
3/30/21
|
4/28/22
|
4/28/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
91.28
|
83.29
|
88.82
|
81.77
|
217.8
|
63.43
|
EBITDA
1 |
-289
|
-224.3
|
-307.8
|
-386.2
|
-258.2
|
-331.4
|
EBIT
1 |
-334.6
|
-270.5
|
-347.9
|
-423.8
|
-296.8
|
-365.6
|
Operating Margin
|
-366.52%
|
-324.71%
|
-391.71%
|
-518.35%
|
-136.24%
|
-576.36%
|
Earnings before Tax (EBT)
1 |
-343.7
|
-285
|
-388.8
|
-441.5
|
-271.8
|
-361.3
|
Net income
1 |
-343.8
|
-285.1
|
-391.4
|
-443.8
|
-271.9
|
-361.6
|
Net margin
|
-376.6%
|
-342.31%
|
-440.61%
|
-542.8%
|
-124.81%
|
-570.15%
|
EPS
2 |
-3.063
|
-2.480
|
-3.114
|
-3.350
|
-1.912
|
-2.543
|
Free Cash Flow
1 |
-199.8
|
-79.98
|
-171.1
|
-132.7
|
-98.85
|
-153.2
|
FCF margin
|
-218.9%
|
-96.02%
|
-192.59%
|
-162.24%
|
-45.38%
|
-241.53%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/11/19
|
4/1/20
|
3/30/21
|
4/28/22
|
4/28/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
73.8
|
-
|
-
|
-
|
61
|
Net Cash position
1 |
123
|
-
|
174
|
438
|
239
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.3289
x
|
-
|
-
|
-
|
-0.1842
x
|
Free Cash Flow
1 |
-200
|
-80
|
-171
|
-133
|
-98.8
|
-153
|
ROE (net income / shareholders' equity)
|
-33%
|
-36.1%
|
-50.1%
|
-46.3%
|
-30.2%
|
-62%
|
ROA (Net income/ Total Assets)
|
-16.6%
|
-16.1%
|
-20.1%
|
-19.8%
|
-14.3%
|
-25.1%
|
Assets
1 |
2,071
|
1,770
|
1,945
|
2,239
|
1,899
|
1,438
|
Book Value Per Share
2 |
7.890
|
5.900
|
6.660
|
7.280
|
5.380
|
2.830
|
Cash Flow per Share
2 |
2.170
|
1.190
|
3.240
|
5.140
|
3.680
|
1.480
|
Capex
1 |
34.9
|
10.9
|
11.5
|
9.34
|
14.4
|
4.89
|
Capex / Sales
|
38.25%
|
13.08%
|
12.97%
|
11.43%
|
6.61%
|
7.7%
|
Announcement Date
|
4/11/19
|
4/1/20
|
3/30/21
|
4/28/22
|
4/28/23
|
4/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -43.82% | 96.4M | | +20.12% | 126B | | +25.25% | 119B | | +25.56% | 27.95B | | -19.51% | 20.5B | | -14.36% | 17.12B | | -15.63% | 16.1B | | -46.67% | 14.97B | | +11.89% | 14.84B | | +57.74% | 14.38B |
Bio Therapeutic Drugs
|